EGR2 and NLRP3 pathways in sleep apnea-related thinking and mood problems
Official title: Regulatory Mechanisms of EGR2 and NLRP3 Inflammatory Pathways in Cognitive Impairment and Depressive-Anxiety-Like Behaviors Associated With Obstructive Sleep Apnea-Hypopnea Syndrome
Run by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · NCT07120711 · Data updated 2026-11-12
This study will test whether activity in the EGR2 and NLRP3 inflammation pathways is linked to thinking, memory, and mood problems in children and adults with obstructive sleep apnea compared with healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | July 1, 2025 |
| Main results expected | July 22, 2025 |
| Study ends | September 30, 2026 |
| Registry record updated | August 13, 2025 |
| Trial ID | NCT07120711 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 2–18 with obstructive snoring or sleep apnea features on ENT screening and adults >18 with suspected OSAS (chronic snoring, witnessed apneas, or daytime sleepiness) who are not pregnant and do not have severe organ failure or major neurological disease are ideal candidates.
✕Probably not a fit
Patients with congenital craniofacial malformations, severe heart, lung, liver, or kidney failure, major neurological disease, current psychiatric disorders, recent use of immunomodulatory drugs, pregnancy, or participation in another clinical trial are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will enroll children (ages 2–18) and adults (>18) with obstructive sleep apnea-hypopnea syndrome (OSAS) alongside age- and sex-matched healthy volunteers. Children will undergo ENT examinations including nasal endoscopy and X-rays, while adults will receive overnight polysomnography; all participants will complete standardized sleepiness, mood, and cognitive questionnaires. Small blood draws will be collected from all participants and tiny adipose tissue samples obtained when available (for example during surgery) to measure EGR2 and NLRP3 pathway activity and inflammatory markers. Molecular data will be correlated with cognitive screening and mood scores to explore mechanisms linking intermittent hypoxia and inflammation to neurobehavioral symptoms in OSAS.
Why it matters
Potential benefit: If successful, the study could identify molecular markers that explain cognitive and mood problems in OSAS and suggest new targets for prevention or treatment.
How similar studies have gone: Prior research has linked intermittent hypoxia and inflammasome activation including NLRP3 to inflammation and cognitive effects in OSA, but direct clinical correlations involving EGR2 and adipose tissue sampling remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Children aged 2-18 years with obstructive snoring or sleep apnea features on initial ENT outpatient screening. Adults (\>18 years) with suspected OSAS in a sleep or respiratory clinic, presenting with chronic snoring, witnessed apneas, or daytime sleepiness, and without severe chronic heart, liver, kidney failure, psychiatric disorders, or pregnancy. Signed written informed consent by the participant or their legal guardian. Not currently enrolled in any other registered clinical trial. Exclusion Criteria: Presence of congenital craniofacial malformations. Severe heart, lung, liver, or kidney failure, or major neurological disease. Recent use of anti-inflammatory or other immunomodulatory medications. Current psychiatric disorder or pregnancy
Where it's running
-
Shanghai Xinhua hospital
Shanghai, China Recruiting
Study contacts
- Study coordinator: Jiang, PHD,MD
- Email: jianglaimz@sina.com
- Phone: 13817719616
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Creating Health online course for people with rheumatological conditions
This project will test whether an online course about diet and self-care helps adults with rheumatoid arthritis, Sjogren's syndrome, lupus, mixed connective tissue disease, or psoriatic arthritis reduce fatigue and improve quality of life.
-
Ultra-brief digital help while waiting for psychotherapy
This trial tests different versions of a short online program (UKADO) to help adults with depression or anxiety who are waiting for outpatient psychotherapy.
-
Blended (online + in-person) versus face-to-face transdiagnostic group therapy for anxiety and depression
This trial will try whether a blended program (online modules plus group sessions) helps adults with anxiety or depression as much as traditional face-to-face group therapy.
-
Understanding anxiety, depression, and bipolar disorder over time in China
This study tests how anxiety, depressive, and bipolar symptoms change over three years to find patterns that help with earlier recognition and prediction in people aged 12–55.
-
See if personalized CBM-I can help anxious kids ages 10–17
Aimed at youth with Generalized, Separation, or Social Anxiety, the study tests a personalized cognitive bias modification for interpretation (CBM-I) to see if it reduces threat-focused thinking and anxiety.
-
Expectancy Focused Exposure for Anxiety Disorders
We test whether Expectancy Focused Exposure helps reduce anxiety symptoms and prevent fear from coming back better than Anxiety Focused Exposure in adults with anxiety disorders.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.